Shares of enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) have received a consensus rating of "Buy" from the eleven research firms that are covering the company, MarketBeat reports. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $29.78.
A number of brokerages recently weighed in on ENGN. Oppenheimer restated an "outperform" rating and issued a $30.00 price objective on shares of enGene in a report on Tuesday, September 24th. HC Wainwright initiated coverage on enGene in a research report on Monday, December 23rd. They set a "buy" rating and a $25.00 price objective on the stock. Citizens Jmp raised enGene to a "strong-buy" rating in a research note on Monday, November 18th. Raymond James initiated coverage on enGene in a research report on Wednesday, November 27th. They issued an "outperform" rating and a $23.00 price target on the stock. Finally, JMP Securities reissued a "market outperform" rating and set a $18.00 price objective on shares of enGene in a research report on Monday, December 23rd.
Check Out Our Latest Report on enGene
Insider Buying and Selling at enGene
In related news, major shareholder Growth Opportunities F. Forbion acquired 10,153 shares of the firm's stock in a transaction on Wednesday, October 2nd. The stock was bought at an average price of $6.37 per share, for a total transaction of $64,674.61. Following the completion of the purchase, the insider now directly owns 2,446,223 shares of the company's stock, valued at approximately $15,582,440.51. The trade was a 0.42 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have purchased 27,994 shares of company stock worth $181,473 over the last three months. Insiders own 13.70% of the company's stock.
Institutional Trading of enGene
A number of hedge funds and other institutional investors have recently made changes to their positions in ENGN. Logos Global Management LP increased its position in enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company's stock worth $11,316,000 after buying an additional 400,000 shares during the period. Franklin Resources Inc. increased its holdings in shares of enGene by 48.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock valued at $7,854,000 after acquiring an additional 389,918 shares during the period. Point72 Asset Management L.P. increased its holdings in shares of enGene by 1,410.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company's stock valued at $4,376,000 after acquiring an additional 619,100 shares during the period. SR One Capital Management LP purchased a new stake in shares of enGene in the second quarter valued at about $4,715,000. Finally, Wolverine Asset Management LLC acquired a new stake in enGene during the 3rd quarter worth approximately $37,000. Institutional investors and hedge funds own 64.16% of the company's stock.
enGene Trading Down 1.5 %
NASDAQ:ENGN traded down $0.10 during trading hours on Tuesday, reaching $6.65. 154,134 shares of the stock were exchanged, compared to its average volume of 118,433. enGene has a twelve month low of $4.42 and a twelve month high of $18.40. The business has a 50-day moving average of $7.78 and a two-hundred day moving average of $7.67. The company has a market capitalization of $294.04 million, a price-to-earnings ratio of -11.47 and a beta of -0.78. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09.
enGene (NASDAQ:ENGN - Get Free Report) last posted its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.06. On average, equities analysts predict that enGene will post -1.52 EPS for the current year.
About enGene
(
Get Free ReportenGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Further Reading
Before you consider enGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.
While enGene currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
